James L Ferrara, MD
img_James L Ferrara
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Pediatrics
PROFESSOR | Oncological Sciences
PROFESSOR | Immunology & Immunotherapy
Research Topics
Cytokines, Immunological Tolerance, Immunology, Inflammation, Stem Cells, Transplantation
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]
Publications

Selected Publications

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Yu Akahoshi, Nikolaos Spyrou, Daniela Weber, Paibel Aguayo-Hiraldo, Francis Ayuk, Chantiya Chanswangphuwana, Hannah K. Choe, Matthias Eder, Aaron M. Etra, Stephan A. Grupp, Elizabeth O. Hexner, William J. Hogan, Carrie L. Kitko, Sabrina Kraus, Monzr M. Al Malki, Pietro Merli, Muna Qayed, Ran Reshef, Tal Schechter, Evelyn Ullrich, Ingrid Vasova, Matthias Wölfl, Robert Zeiser, Janna Baez, Rahnuma Beheshti, Gilbert Eng, Sigrun Gleich, Nikolaos Katsivelos, Steven Kowalyk, George Morales, Rachel Young, Yi Bin Chen, Ryotaro Nakamura, John E. Levine, James L.M. Ferrara. Blood

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. Zachariah DeFilipp, Haesook T. Kim, Nikolaos Spyrou, Nikolaos Katsivelos, Steven Kowalyk, Gilbert Eng, Stelios Kasikis, Rahnuma Beheshti, Janna Baez, Yu Akahoshi, Francis Ayuk, Hannah Choe, Aaron Etra, Stephan A. Grupp, Elizabeth O. Hexner, William J. Hogan, Carrie L. Kitko, Muna Qayed, Ran Reshef, Ingrid Vasova, Robert Zeiser, Rachel Young, Ernst Holler, James L.M. Ferrara, Ryotaro Nakamura, John E. Levine, Yi Bin Chen. Blood advances

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD. Aaron Etra, Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon, Stephanie Gergoudis, George Morales, Nikolaos Spyrou, Steven Kowalyk, Paibel Aguayo-Hiraldo, Yu Akahoshi, Francis Ayuk, Janna Baez, Brian C. Betts, Chantiya Chanswangphuwana, Yi Bin Chen, Hannah Choe, Zachariah DeFilipp, Sigrun Gleich, Elizabeth Hexner, William J. Hogan, Ernst Holler, Carrie L. Kitko, Sabrina Kraus, Monzr Al Malki, Margaret MacMillan, Attaphol Pawarode, Francesco Quagliarella, Muna Qayed, Ran Reshef, Tal Schechter, Ingrid Vasova, Daniel Weisdorf, Matthias Wölfl, Rachel Young, Ryotaro Nakamura, James L.M. Ferrara, John E. Levine, Shernan Holtan. Blood advances

View All Publications

Precision BMT Through Biomarkers

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Ferrara during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Realta Life sciences
  • Allovir
  • Incyte Corporation
  • Bo Fu Rui
  • IQVIA
  • Physicians Education Research
  • Resolution Therapeutics
  • Editas Medicine, Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.